====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ======

Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on [[mapk_pathway_drugs_ocular_toxicity|RAF/MEK pathway inhibitors]], applicable to tovorafenib and its drug class.

===== Baseline Ophthalmologic Assessment =====

A **baseline ophthalmologic examination** is recommended before initiating MEK or RAF inhibitor therapy, though there is currently no formal FDA mandate for routine screening in all patients.((Jeng-Miller KW, Miller MA, Heier JS. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation. //The Oncologist//. 2024;29(5):e616-e621. [[https://doi.org/10.1093/oncolo/oyae014|DOI]])) This baseline evaluation serves to differentiate preexisting pathology from treatment-emergent MEK inhibitor-associated retinopathy (MEKAR) and should include:

  * **Best-corrected visual acuity (BCVA)***
  * **Dilated fundus examination***
  * **Optical coherence tomography (OCT)** — the most sensitive tool for detecting subclinical subretinal fluid((Francis JH, Habib LA, Abramson DH, et al. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences From Central Serous Chorioretinopathy. //Ophthalmology//. 2017;124(12):1788-1798. [[https://doi.org/10.1016/j.ophtha.2017.05.038|DOI]]))((Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. //JAMA Ophthalmology//. 2016;134(8):855-62. [[https://doi.org/10.1001/jamaophthalmol.2016.0090|DOI]]))*
  * Color vision testing and visual field assessment as clinically indicated((Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK Inhibitor-Associated Retinopathy in Metastatic Melanoma. //Ann Oncol//. 2014;25(7):1437-1441. [[https://doi.org/10.1093/annonc/mdu169|DOI]]))*

The NCCN Guidelines for Histiocytic Neoplasms specifically recommend that **monitoring by retinal exam with OCT is recommended** for patients on MEK inhibitors.((Histiocytic Neoplasms. National Comprehensive Cancer Network. Updated 2026-05-08.)) A real-world study of MEK inhibitor use in histiocytic neoplasms found that baseline retinal exams were performed in only 49.4% of patients, highlighting a gap in practice.((Abstracts From the 41st Annual Meeting of the Histiocyte Society. //Pediatr Blood Cancer//. 2025;72 Suppl 5:e70014. [[https://doi.org/10.1002/1545-5017.70014|DOI]]))

===== Ongoing Monitoring Schedule =====

  * **Assess for visual symptoms at each visit** — the binimetinib (Mektovi) FDA label explicitly requires this.((Food and Drug Administration. MEKTOVI (binimetinib) prescribing information. 2025. [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s006lbl.pdf|FDA Label]]))*
  * **Perform ophthalmologic examination at regular intervals**, for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings.*
  * In clinical trials of binimetinib, patients were monitored with OCT **biweekly for the first 2 months, then monthly** thereafter. This represents a reasonable protocol for higher-risk patients.*
  * **Regular ophthalmologic examination is particularly appropriate** for patients at increased risk, including those with a history of ocular inflammation, infection, or underlying macular/retinal disease.*

===== Timing of Onset =====

Understanding the typical timeline helps guide monitoring intensity:

  * Median time to onset of serous retinopathy with cobimetinib: **15 days** (range 7–111 days)((Barteselli G, Goodman GR, Patel Y, et al. Characterization of Serous Retinopathy Associated With Cobimetinib: Integrated Safety Analysis of Four Studies. //Drug Saf//. 2022;45(12):1491-1499. [[https://doi.org/10.1007/s40264-022-01248-2|DOI]]))*
  * Median time to subretinal fluid detection by OCT: **14 days**, with 80% of patients showing abnormal OCT findings within the first 28-day cycle((Sever A, Dotan G, Brik D, et al. Ocular Safety and Visual Acuity Stability in Pediatric Patients With Optic Pathway Gliomas and Orbital Plexiform [Neurofibromas](https://www.openevidence.com/rare-disease/neurofibroma) Treated With BRAF and MEK Inhibitors. //Pediatr Blood Cancer//. 2025;72(7):e31709. [[https://doi.org/10.1002/pbc.31709|DOI]]))*
  * Median time to onset with binimetinib: **1.2 months** (range 0–17.5 months)*

===== Management of Specific Ocular Toxicities =====

==== MEK Inhibitor-Associated Retinopathy (MEKAR) / Serous Retinal Detachment ====

  * Most cases are **mild, self-limited, and reversible** — 48% of cobimetinib-associated serous retinopathy cases resolved without any dose modification.*
  * For **retinal pigment epithelial detachment (RPED)**: the trametinib FDA label recommends withholding the drug for up to 3 weeks. If improved, resume at the same or lower dose. If not improved, permanently discontinue or resume at a lower dose.((Food and Drug Administration. Mekinist (trametinib) prescribing information. 2026. [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204114s024lbl.pdf|FDA Label]]))*
  * In pediatric patients, MEKAR resolved within **1–2 weeks** of drug discontinuation, and OCT confirmed complete resolution.*
  * Importantly, cessation of life-extending MEK inhibitor therapy is **not indicated** when subretinal fluid is present without significant visual impairment.*

==== Retinal Vein Occlusion (RVO) ====

  * This is a rare but serious event requiring **permanent discontinuation** of the MEK inhibitor (per the trametinib FDA label).*

==== Uveitis (primarily with BRAF inhibitors) ====

  * Typically managed with **dose reduction** of the BRAF inhibitor and topical corticosteroids. Uveitis generally resolves completely upon drug discontinuation.*

===== Dose Modification Framework =====

Based on the trametinib FDA label:

^ Ocular Toxicity ^ Management ^ References ^
| RPED (any grade) | Withhold for up to 3 weeks; if improved, resume at same or lower dose; if not improved, discontinue or reduce dose | Jeng-Miller et al. 2024; Trametinib FDA label |
| Retinal vein occlusion | Permanently discontinue | Trametinib FDA label |
| Serous retinopathy (mild, asymptomatic) | May continue treatment with close monitoring; dose modification at physician discretion | Francis et al. 2017; Weber et al. 2016 |
| Serous retinopathy (symptomatic, Grade ≥2) | Withhold; resume at lower dose upon resolution | Weber et al. 2016 |
| Uveitis (BRAF inhibitor-related) | Dose reduction; topical steroids; discontinue if refractory | Urner-Bloch et al. 2014; Mettler et al. 2021 |

===== Key Practical Recommendations =====

  * **Multidisciplinary communication** between oncology and ophthalmology is essential — ocular adverse events are often associated with other systemic adverse effects that may independently require dose modification.((Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular Adverse Events Associated With MEK Inhibitors. //Retina//. 2019;39(8):1435-1450. [[https://doi.org/10.1097/IAE.0000000000002451|DOI]]))*
  * Long-term MEK inhibitor use may cause **retinal thinning** that, while currently without functional relevance, warrants continued monitoring even after initial retinopathy resolves.((Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK Inhibitor-Associated Retinopathy (MEKAR) in Metastatic Melanoma: Long-Term Ophthalmic Effects. //Eur J Cancer//. 2016;65:130-8. [[https://doi.org/10.1016/j.ejca.2016.06.018|DOI]]))*
  * Patients should be counseled to report any **new visual symptoms** (blurred vision, color vision changes, photopsia, visual field defects) promptly, as early detection allows for timely intervention and typically full reversibility.*

===== References =====

  - Jeng-Miller KW, Miller MA, Heier JS. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation. //The Oncologist//. 2024;29(5):e616-e621. [[https://doi.org/10.1093/oncolo/oyae014|DOI]]
  - Francis JH, Habib LA, Abramson DH, et al. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences From Central Serous Chorioretinopathy. //Ophthalmology//. 2017;124(12):1788-1798. [[https://doi.org/10.1016/j.ophtha.2017.05.038|DOI]]
  - Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. //JAMA Ophthalmology//. 2016;134(8):855-62. [[https://doi.org/10.1001/jamaophthalmol.2016.0090|DOI]]
  - Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK Inhibitor-Associated Retinopathy in Metastatic Melanoma. //Ann Oncol//. 2014;25(7):1437-1441. [[https://doi.org/10.1093/annonc/mdu169|DOI]]
  - Histiocytic Neoplasms. National Comprehensive Cancer Network. Updated 2026-05-08.
  - Abstracts From the 41st Annual Meeting of the Histiocyte Society. //Pediatr Blood Cancer//. 2025;72 Suppl 5:e70014. [[https://doi.org/10.1002/1545-5017.70014|DOI]]
  - Food and Drug Administration. MEKTOVI (binimetinib) prescribing information. 2025. [[https://www.accessdata.fda.gov/drugsatfda*docs/label/2023/210498s006lbl.pdf|FDA Label]]*
  - Barteselli G, Goodman GR, Patel Y, et al. Characterization of Serous Retinopathy Associated With Cobimetinib: Integrated Safety Analysis of Four Studies. //Drug Saf//. 2022;45(12):1491-1499. [[https://doi.org/10.1007/s40264-022-01248-2|DOI]]
  - Sever A, Dotan G, Brik D, et al. Ocular Safety and Visual Acuity Stability in Pediatric Patients With Optic Pathway Gliomas and Orbital Plexiform Neurofibromas Treated With BRAF and MEK Inhibitors. //Pediatr Blood Cancer//. 2025;72(7):e31709. [[https://doi.org/10.1002/pbc.31709|DOI]]
  - Food and Drug Administration. Mekinist (trametinib) prescribing information. 2026. [[https://www.accessdata.fda.gov/drugsatfda*docs/label/2024/204114s024lbl.pdf|FDA Label]]*
  - Mettler C, Monnet D, Kramkimel N, et al. Ocular Safety Profile of BRAF and MEK Inhibitors: Data From the World Health Organization Pharmacovigilance Database. //Ophthalmology//. 2021;128(12):1748-1755. [[https://doi.org/10.1016/j.ophtha.2021.05.008|DOI]]
  - Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular Adverse Events Associated With MEK Inhibitors. //Retina//. 2019;39(8):1435-1450. [[https://doi.org/10.1097/IAE.0000000000002451|DOI]]
  - Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK Inhibitor-Associated Retinopathy (MEKAR) in Metastatic Melanoma: Long-Term Ophthalmic Effects. //Eur J Cancer//. 2016;65:130-8. [[https://doi.org/10.1016/j.ejca.2016.06.018|DOI]]

{{tag>drugs}}